Abstract:Tinea capitis is a common superficial fungal infection of the scalp in children, particularly in those of African descent. Trichophyton tonsuran, an anthropophilic dermatophyte, is responsible for the majority of cases in North America. The clinical presentations are variable and include: (i) a "seborrheic" form that is scaling, often without noticeable hair loss; (ii) a pustular, crusted pattern, either localized or more diffuse; (iii) a "black dot" variety characterized by small black dots within areas of alopecia; (iv) a kerion, which is an inflammatory mass; and (v) a scaly, annular patch. Most experts still consider griseofulvin to be the drug of choice, but recommend a higher dosage of 20-25 mg/kg/day for 8 weeks because of the increase in treatment failures. Despite a history of having an excellent tolerability profile, the long treatment course and higher doses required for griseofulvin have led to consideration of new antifungal agents for this infection. Terbinafine, itraconazole, and fluconazole compartmentalize in skin, hair, and nails, thereby allowing shorter treatment courses of < or =4 weeks. All have generally been shown to be effective in the treatment of tinea capitis and appear relatively well tolerated, with gastrointestinal symptoms being the most common adverse effect. Monitoring for liver enzyme elevations is generally unnecessary if therapy is limited to </=4 weeks. As more data regarding efficacy, tolerability, and dose administration becomes available, one or more of these new antifungal agents may become first-line therapy for tinea capitis. For now, we recommend their use in cases of treatment failure or recurrent noncompliance. Our personal preference in the younger child is fluconazole. It has a favorable tolerability profile and is available in liquid form. In the older child who can take a tablet, terbinafine is recommended. More data is available on this drug in the treatment of tinea capitis than the other two, and it is the least expensive. Although the oral antifungal agents are the most important aspect of therapy, adjunctive therapy may be beneficial. Sporicidal shampoos, such as selenium sulfide, can aid in removing adherent scales and hasten the eradication of viable spores from the scalp in the hope of decreasing the spread of this infection. The use of corticosteroids for the treatment of kerions is controversial. Many of the studies have design flaws or show variable results. We recommend either a short burst of oral corticosteroids or topical corticosteroids in patients with the most severe disease.

Scalp Infection, Inflammation, and Infestation

Mini-Review: the Diagnostic Methods of Tinea Capitis

Common skin conditions affecting the scalp: Tinea Capitis, Pediculosis Capitis, Seborrhoeic Dermatitis, Dandruff, Psoriasis

Tinea capitis: epidemiology, diagnosis and management strategies

Clinical Diagnosis of Common Scalp Disorders

A Current Diagnostic and Therapeutic Challenge: Tinea Capitis

Tinea capitis: epidemiology, diagnosis, treatment, and control

Tinea capitis: A single-institution retrospective review from 2010 to 2015

Clinical Consequences of Delayed Treatment for Tinea Capitis (Ringworm of the Scalp): A Case Report

New treatments for tinea capitis

Microsporum canis-Induced Tinea Capitis: A Rapid Screening Algorithm

Scalp microbiome: a guide to better understanding scalp diseases and treatments

Overview of Scalp Conditions

Current topics of tinea capitis in China.

Histopathology in the Diagnosis of Tinea Capitis: When to Do, How to Interpret?

Tinea capitis: dermoscopy and calcium fluorescent microscopy as highly efficient and precise diagnostic tools

An update on tinea capitis in children

International Journal of Biological & Medical Research Aclinical Spectrum of Scalp Dermatoses in Adults Presenting to a Tertiary Referral Care Centre. a B

Tinea capitis in Adults: Misdiagnosis or Reappearance?

Tinea capitis in adults

Management of tinea capitis in infants and children in the United States: A national survey of pediatric dermatologists